Welcome to our dedicated page for OSR Health SEC filings (Ticker: OSRH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OSR Holdings, Inc. (NASDAQ: OSRH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. OSR Holdings is a global healthcare holding company engaged through its subsidiaries in immuno-oncology, regenerative biologics, and medical device technologies, and its filings offer detailed information on corporate transactions, governance, financing arrangements, and listing status.
Investors can review Form 8-K current reports where OSR Holdings describes material events such as share exchange agreements, licensing term sheets, financing amendments, and notices from The Nasdaq Stock Market LLC. For example, 8-K filings outline the Share Exchange Agreement under which OSR Holdings Co., Ltd. will acquire all issued and outstanding shares of Woori IO Co., Ltd., making Woori IO a wholly owned subsidiary, and describe Woori IO’s non-invasive biosensing technology for glucose monitoring. Other 8-Ks detail Vaximm AG’s non-binding and binding term sheets with BCM Europe AG for potential global licensing of the VXM01 oral cancer immunotherapy platform, including exclusivity periods and proposed financial structures.
The company’s proxy materials, such as the Definitive Proxy Statement on Schedule DEF 14A, set out proposals for director elections, advisory votes on executive compensation, share-based incentive plans under the 2025 Omnibus Incentive Plan, and approvals under Nasdaq Listing Rule 5635(d) for potential issuances of common stock or related securities in excess of 20% of outstanding shares. These documents also confirm OSR Holdings’ status as an emerging growth company and describe its principal executive offices and meeting logistics.
Filings also include disclosures related to Nasdaq listing compliance, such as the Form 8-K describing receipt of a minimum bid price deficiency notice under Listing Rule 5550(a)(2), along with the company’s stated intention to monitor its share price and consider options to regain compliance. Additional 8-Ks cover amendments to a Note Purchase Agreement and Common Stock Purchase Warrant with White Lion Capital, LLC, clarifying exchange caps and shareholder approval requirements.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key terms, conditions, and implications for OSR Holdings’ capital structure and strategic direction. Users can quickly scan material agreements, governance proposals, and listing updates, and then drill down into the full-text filings for deeper analysis, including exhibits such as term sheets, annexes, and press releases incorporated by reference.
OSR Health, Inc. (OSRH) reports that a Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026 at 10:00 a.m. Eastern Time regarding the company’s appeal of a Nasdaq staff determination to delist its securities. A timely hearing request was submitted on August 25, 2026, which stayed the filing of a Form 25-NSE and therefore the formal delisting from Nasdaq, but did not prevent the suspension of trading in OSR Health’s securities that took effect at the opening of business on August 26, 2026. The company is preparing a comprehensive plan to regain and sustain compliance with Nasdaq’s continued listing requirements and intends to advocate for continued listing, while cautioning that there can be no assurance the Panel will grant its request or that compliance will be regained.
OSR Health, Inc. (OSRH) reports an update on its Nasdaq listing status. Nasdaq staff previously determined to delist the company’s common stock and warrants from the Nasdaq Capital Market for non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On August 25, 2026, OSR Health requested a hearing before a Nasdaq Hearings Panel to appeal the delisting determination and asked for continued listing of its securities. The company states that trading in its securities is still scheduled to be suspended at the opening of business on August 26, 2026, despite the hearing request. The hearing request is expected to stay the filing of a Form 25-NSE, delaying formal delisting and deregistration while the Panel reviews the case. OSR Health plans to present a compliance plan but cautions there is no assurance the Panel will grant continued listing or that it will regain compliance.
OSR Health, Inc. (symbol OSRH) disclosed that Nasdaq has issued a Staff Determination to delist its common stock and warrants from the Nasdaq Capital Market for failure to meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq plans to suspend trading in OSRH common stock and warrants at the opening of business on August 26, 2026, and to file a Form 25-NSE to remove the securities from listing and registration.
The company intends to request a hearing before a Nasdaq Independent Hearings Panel under the Nasdaq Listing Rule 5800 Series. A timely hearing request is expected to stay the filing of the Form 25-NSE, but will not stay the trading suspension. OSR Health highlights recent trading activity, including approximately 370 million and 145 million shares traded on August 17 and 18, 2026, respectively, versus a public float of about 18.5 million shares, and notes its share price reached an intraday high of $0.84 on August 18, still short of the $1.00 compliance level.
OSR Health, Inc. received an amended Schedule 13G/A from joint protein central, inc., a Korean entity, reporting its ownership in the company’s common stock. The investor reports beneficial ownership of 1,200,000 shares of common stock, representing 3.4% of OSR Health’s outstanding common stock.
The filing states that joint protein central, inc. has sole voting power and sole dispositive power over all 1,200,000 shares, with no shared voting or dispositive power. The ownership is explicitly reported as 5 percent or less of the class, reflecting a non-controlling but still notable minority position.
OSR Health, Inc., a healthcare holding company focused on immunotherapies, biologics and medical devices, reported substantially lower losses but sharply reduced revenue for the quarter and six months ended June 30, 2026. Net sales were $315,669 for the quarter and $799,727 for the first half of 2026, down 72% and 58% from the prior-year periods, largely reflecting a shift at subsidiary RMC from a purchase-and-resale model to a consignment, commission-based arrangement and prior one-time inventory sales.
Gross profit nonetheless improved, with quarterly gross margin rising from about 3% to 27%. Operating loss was $3.0 million for the quarter and $6.7 million year-to-date, both narrower than 2025, aided by lower SG&A and the absence of 2025 business-combination costs. Net loss attributable to OSR Health was $3.8 million for the first half. Total assets were $166.6 million and total liabilities $41.7 million.
Liquidity remains tight: cash and cash equivalents were $1.5 million, with $3.4 million of net cash used in operations in the first half. The company is relying on an $80 million equity line of credit, under which it has raised $3.38 million to date, and a 5% convertible note with a fixed $1.00 conversion price and a potential discounted alternative price if Nasdaq non-compliance is not cured. In June 2026, OSR announced a shareholder loyalty CVR program that may deliver up to 5 additional shares per share if specified price thresholds are met over 12 months. Management confirms ongoing material weaknesses in internal control over financial reporting, particularly around liabilities and accounting staffing, and states that remediation efforts are in progress.
OSR Health, Inc. reported results of its August 7, 2026 annual stockholder meeting. As of the July 8, 2026 record date, there were 35,118,692 common shares outstanding. A total of 21,088,120 shares, or 60.05% of shares entitled to vote, were represented, constituting a quorum.
Stockholders re-elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more than 15.17 million votes “for” and roughly 0.12–0.13 million votes “withheld.” Stockholders also approved ratification of the independent auditor with 20,296,535 votes “for,” the advisory executive compensation proposal with 15,059,135 votes “for,” and an Authorized Shares Increase Proposal with 19,922,498 votes “for” versus 581,009 “against.”
OSR Health, Inc. issued a clarification about earlier statements describing Nasdaq’s views on its Shareholder Loyalty Contingent Value Rights (CVR) program. The company explained that language in its July 31, 2026 release should not be read as implying Nasdaq has approved or endorsed the CVR program.
OSR Health stated that Nasdaq’s prior feedback was a preliminary, verbal response limited to a technical question about whether the CVR program would trigger a mechanical stock price adjustment, such as an ex-date adjustment, and that Nasdaq has expressed no definitive opinion on the program more broadly. The clarification confirms that the previously announced August 14, 2026 record date for the Shareholder Loyalty CVR program remains unchanged.
OSR Health, Inc. reported that Nasdaq, in a verbal communication, stated the company’s Shareholder Loyalty Contingent Value Rights (CVR) program will not cause any mechanical adjustment to the price of its common stock, either when CVRs are distributed or when additional shares are delivered to enrolled holders.
Under this loyalty CVR program, shareholders of record on August 14, 2026 who enroll receive one CVR for each share of OSRH common stock and may receive additional shares at no cost if specified closing-price thresholds are met on four measurement dates over the following twelve months. Nasdaq’s view applies only to price-adjustment mechanics and is not an endorsement; the CVR distribution and share deliveries remain subject to separate securities-law and regulatory processes.
OSR Health, Inc. is calling a virtual annual meeting on August 7, 2026 at 10:00 a.m. Eastern Time to vote on four proposals. Holders of 35,118,692 shares of common stock outstanding as of July 8, 2026 may vote to re-elect seven directors, ratify RSM Korea as auditor, approve an advisory Say‑on‑Pay resolution on 2025 executive compensation, and increase authorized common stock from 100,000,000 to 250,000,000 shares.
The Board cites flexibility for a proposed shareholder loyalty program, future financings, strategic transactions and general corporate purposes as reasons for the share increase, while acknowledging potential dilution and possible anti-takeover effects. As of June 30, 2026, CEO Kuk Hyoun Hwang beneficially owned 13,069,106 shares, or 36.8% of common stock, giving him significant influence. In 2025 he received $400,000 in salary; the CSO and CFO received $345,000 and $300,000, respectively. A 2025 Omnibus Incentive Plan reserves 6,300,000 shares for future equity awards, though no stock-based grants had been made by year-end.
OSR Health, Inc. is soliciting proxies for its virtual Annual Meeting on to vote on four proposals, including re-election of seven directors, ratification of RSM Korea as auditor, a non-binding advisory Say-on-Pay, and a proposal to increase authorized common shares from 100,000,000 to 250,000,000.
The Board recommends a vote FOR all proposals. The Authorized Shares Increase is presented to support a proposed shareholder loyalty program, future financings, strategic transactions, and general corporate purposes; if approved, the amendment will be effective upon filing with the Delaware Secretary of State.